Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
Open Access
- 30 June 2009
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 101 (2), 219-224
- https://doi.org/10.1038/sj.bjc.6605162
Abstract
Background: Methods: Results: Conclusions:Keywords
This publication has 16 references indexed in Scilit:
- Targeted Agents: The Rules of CombinationClinical Cancer Research, 2007
- American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late EffectsJournal of Clinical Oncology, 2007
- Impaired angiogenesis in aminopeptidase N-null miceProceedings of the National Academy of Sciences, 2007
- Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional TherapiesCancer Research, 2006
- Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-αClinical Cancer Research, 2006
- Tumor Vascular Targeting with Tumor Necrosis Factor α and Chemotherapeutic DrugsAnnals of the New York Academy of Sciences, 2004
- Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alterationJCI Insight, 2002
- Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock.JCI Insight, 1998
- Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancyEuropean Journal of Cancer and Clinical Oncology, 1991
- Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins.The Journal of Experimental Medicine, 1989